We are glad to announce that Dr. Monika Kluzek, who will soon join IMol as a Group Leader, has been awarded the NCN OPUS 26 Grant.
The funding will allow her to realize the project which studies intratumoral bacteria that work with cancer cells, reducing the effectiveness of chemotherapy. As Monika says:
“We plan to use the bacteria’s communication system to camouflage antibiotic therapy. By targeting specific bacterial membranes in the tumor, we aim to improve cancer treatment outcomes.”
Congratulations!
